Immunomodulation and antiangiogenesis in cancer therapy. from basic to clinical research
Scharovsky, O.G.; Matar, P.; Rozados, V.R.; Rico, M.ía.J.; Zacarías Fluck, M.F.; Mainetti, L.E.; Fernández Zenóbi, M.V.; Roggero, E.A.; Gervasoni, S.I.; Rossa, A.; Perroud, H.án.A.; Sánchez, A.M.; Celoria, G.C.; Font, M.ía.T.
Medicina 72(1): 47-57
2012
ISSN/ISBN: 0025-7680 PMID: 22257459 Document Number: 660207
Basic and pre-clinic research in cellular and molecular oncology are the main supports accounting for the advancement in cancer therapeutics. The findings achieved, and their implementation in clinical practice are responsible for the permanent improvement in the treatment of the neoplastic disease. Our present objective is to summarize and discuss the pre-clinical findings in immunomodulation and anti-angiogenesis for the treatment of several types of tumors obtained in our Institute during the last 15 years, and the subsequent translation and application of the acquired experimental knowledge in a Phase I/II Clinical Trial. We present the results and mechanisms of action of antimetastatic immunomodulation with cyclophosphamide, the metronomic chemotherapy with different single drugs and their combinations, and finally the design and preliminary results of a clinical trial with metronomic chemotherapy for patients with advanced breast cancer.